gvtcx

NHS Framework Agreement - North of England - Tranche B

NHS England Published 6 Oct 2017 Contracts Finder
The value below is a framework or dynamic market ceiling: the maximum that could be spent across all call-offs, not the value of a single contract. Aggregate figures on this site exclude these to avoid double counting.

key details

Value£521,100,000
Statuscomplete
Category (CPV) 33600000
RegionNorth East, North West, Yorkshire and the Humber
Deadline7 Nov 2017
Contract start1 Mar 2018
Contract end29 Feb 2020
Procedureopen
SME suitableYes
OCIDocds-b5fd17-cbf2fcb1-162c-40a1-a1a8-b258187390fb

Awards (60)

This procurement was awarded to 60 suppliers. Values shown are per-award; the notice total is £521,100,000.

SupplierValueDateStatus
Astellas Pharma Ltd shared £521,100,000 13 Feb 2018 active
ASTELLAS PHARMA LTD. shared £521,100,000 8 Jan 2018 active
AVENTIS PHARMA LIMITED T/A SANOFI shared £521,100,000 8 Jan 2018 active
Aventis Pharma Ltd trading as Sanofi shared £521,100,000 13 Feb 2018 active
Bayer Plc shared £521,100,000 13 Feb 2018 active
BAYER PUBLIC LIMITED COMPANY shared £521,100,000 8 Jan 2018 active
BIOGEN IDEC LIMITED shared £521,100,000 8 Jan 2018 active
Biogen Ltd. shared £521,100,000 13 Feb 2018 active
Boehringer Ingelheim shared £521,100,000 13 Feb 2018 active
BRISTOL-MYERS SQUIBB PHARMACEUTICALS LIMITED shared £521,100,000 8 Jan 2018 active
Bristol-Myers Squibb Pharmaceuticals Ltd. shared £521,100,000 13 Feb 2018 active
DAIICHI SANKYO UK LIMITED shared £521,100,000 8 Jan 2018 active
Daiichi Sankyo UK Ltd shared £521,100,000 13 Feb 2018 active
ELI LILLY AND COMPANY LIMITED shared £521,100,000 8 Jan 2018 active
ELI LILLY & COMPANY LIMITED shared £521,100,000 13 Feb 2018 active
Ferring Pharmaceuticals Limited shared £521,100,000 13 Feb 2018 active
FERRING PHARMACEUTICALS LIMITED shared £521,100,000 8 Jan 2018 active
GEDEON RICHTER (UK) LIMITED shared £521,100,000 8 Jan 2018 active
Gedeon Richter UK Ltd shared £521,100,000 13 Feb 2018 active
GENZYME THERAPEUTICS LIMITED shared £521,100,000 8 Jan 2018 active
Genzyme Therapeutics Ltd shared £521,100,000 13 Feb 2018 active
Gilead Sciences shared £521,100,000 13 Feb 2018 active
GILEAD SCIENCES LTD shared £521,100,000 8 Jan 2018 active
INTRAPHARM LABORATORIES LIMITED shared £521,100,000 8 Jan 2018 active
Intrapharm Laboratories Ltd shared £521,100,000 13 Feb 2018 active
Ipsen Limited shared £521,100,000 13 Feb 2018 active
IPSEN LIMITED shared £521,100,000 8 Jan 2018 active
JANSSEN-CILAG LIMITED shared £521,100,000 8 Jan 2018 active
Janssen-Cilag Ltd shared £521,100,000 13 Feb 2018 active
LEO Pharma shared £521,100,000 13 Feb 2018 active
LEOPHARMA LIMITED shared £521,100,000 8 Jan 2018 active
Merck shared £521,100,000 13 Feb 2018 active
MERCK SERONO LIMITED shared £521,100,000 8 Jan 2018 active
MERCK SHARP & DOHME LIMITED shared £521,100,000 8 Jan 2018 active
Mercury Pharmaceuticals Limited shared £521,100,000 13 Feb 2018 active
MERCURY PHARMACEUTICALS LIMITED shared £521,100,000 8 Jan 2018 active
MSD shared £521,100,000 13 Feb 2018 active
NAPP PHARMACEUTICALS LIMITED shared £521,100,000 8 Jan 2018 active
Napp Pharmaceuticals Ltd shared £521,100,000 13 Feb 2018 active
NOVARTIS PHARMACEUTICALS UK LIMITED shared £521,100,000 8 Jan 2018 active
Novartis Pharmaceuticals UK Ltd shared £521,100,000 13 Feb 2018 active
NOVO NORDISK LIMITED shared £521,100,000 8 Jan 2018 active
Novo Nordisk Ltd shared £521,100,000 13 Feb 2018 active
OEHRINGER INGELHEIM LIMITED shared £521,100,000 8 Jan 2018 active
PFIZER LIMITED shared £521,100,000 8 Jan 2018 active
Pfizer Ltd shared £521,100,000 13 Feb 2018 active
PHARMASURE LIMITED shared £521,100,000 8 Jan 2018 active
Pharmasure Ltd shared £521,100,000 13 Feb 2018 active
ROCHE PRODUCTS LIMITED shared £521,100,000 8 Jan 2018 active
Roche Products Ltd shared £521,100,000 13 Feb 2018 active
ROVI Biotech Limited shared £521,100,000 13 Feb 2018 active
ROVI BIOTECH LIMITED shared £521,100,000 8 Jan 2018 active
SANDOZ LIMITED shared £521,100,000 8 Jan 2018 active
Sandoz Ltd shared £521,100,000 13 Feb 2018 active
TAKEDA UK shared £521,100,000 13 Feb 2018 active
TAKEDA UK LIMITED shared £521,100,000 8 Jan 2018 active
TEVA UK LIMITED shared £521,100,000 8 Jan 2018 active
TEVA UK Ltd shared £521,100,000 13 Feb 2018 active
UCB PHARMA LIMITED shared £521,100,000 8 Jan 2018 active
UCB PHARMA LTD shared £521,100,000 13 Feb 2018 active

description

A framework is awarded for the supply of proprietary pharmaceuticals to participating Authorities in the NHS Region: North of England. The period of the resulting framework is 01 March 2018 - 29 February 2020, with an option to extend (at the Authority's discretion) for a period or periods up to a total of 24 months.

Additional information:

Attached is the model form framework agreement. All of the awarded frameworks were made on the basis of the model form framework agreement.

Redacted award schedules have been attached for each of the awarded suppliers.

documents

Documents are linked, not mirrored. They are served by the publishing authority and may require registration.

notice history

2 notices published against this procurement.

PublishedTypeRegimeNotice
19 Apr 2018 Award (award) · 8b9605ea-7683-4e1b-b9f6-f77c319142d5-211910
10 May 2018 Award (award) · d5f7ca8a-6013-46c6-94ea-631f64bd61b5-215390

more from NHS England

all contracts from this buyer →

similar contracts awarded

Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.

source

Published on Contracts Finder. Contact details for named individuals are not reproduced on this site.